2015 Dealmaking Outlook

March’s program was held at the Nippon Club. To download the event flyer, click here.

(click here for speaker bios)

Jocelyn Trokenheim
Head of Global Business Development Office and Strategy, Takeda Pharmaceuticals International

Elaine Jones, PhD
Executive Director, Venture Capital, Pfizer

Brianne Weingarten
Executive Director, Alliance Management, Purdue Pharma L.P.

Alan Paau, MBA, PhD
Chairman, Guangda Cooperation International Technology Center, Co. Ltd; Former Vice Provost for Technology Commercialization – Global Initiatives, Cornell University

Ed Saltzman, President & Founder, Defined Health

2014 was marked by record levels of biopharma M&A activity and a strong IPO market.  43 deals worth $73.6 billion were made in the first three quarters of 2014 versus 42 deals worth $39.9 billion in the entire 2013.  Activity was particularly high in the US compared to Europe and Asia. Also, specialty and generic pharma deals surged.

At this program, seasoned deal makers will share the insights and discuss how different types of pharma companies are accessing innovations. Ed Saltzman of Defined Health will facilitate the discussion after giving an overview on the current state of dealmaking. Some of the trends he sees include:

  • Outsourcing of discovery and early development by big pharma
  • More VC and IPO money coming into early biotech start ups
  • More creativity and flexibility as to deal structure on the part of pharma
  • Increasing up-front payments
  • Immuno-oncology bubble
  • Pharma-Pharma risk sharing deals

We expect to have an interactive discussion and welcome questions from the audience.